


CLAIMS

1. A compound represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof:



(I)

wherein

X and Z each represent CH or N;

R¹, R², and R³, which may be the same or different, represent a hydrogen atom, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₂₋₆ alkenyl, C₂₋₆ alkynyl, nitro, or amino, which C₁₋₆ alkyl, C₁₋₆ alkoxy, C₂₋₆ alkenyl, and C₂₋₆ alkynyl are optionally substituted by a halogen atom; hydroxyl; C₁₋₄ alkoxy; C₁₋₄ alkoxy carbonyl; amino on which one or two hydrogen atoms are optionally substituted by C₁₋₄ alkyl optionally substituted by hydroxyl or C₁₋₄ alkoxy; group R¹²R¹³N-C(=O)-O- wherein R¹² and R¹³, which may be the same or different, represent a hydrogen atom or C₁₋₄ alkyl which alkyl is optionally substituted by hydroxyl or C₁₋₄ alkoxy; or group R¹⁴-(S)m- wherein R¹⁴ represents a saturated or unsaturated three- to seven-membered carbocyclic or heterocyclic group optionally substituted by C₁₋₄ alkyl and m is 0 or 1;

R⁴ represents a hydrogen atom;

R⁵, R⁶, R⁷, and R⁸, which may be the same or different, represent a hydrogen atom, a halogen atom, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ alkylthio, nitro, or amino, provided that R⁵, R⁶, R⁷, and R⁸ do not simultaneously represent a hydrogen atom;

*B¹
cont*

~~R⁹ and R¹⁰, which may be the same or different, represent a hydrogen atom, C₁₋₆ alkyl, or C₁₋₄ alkylcarbonyl, the alkyl portion of which C₁₋₆ alkyl or C₁₋₄ alkylcarbonyl is optionally substituted by a halogen atom; C₁₋₄ alkoxy; amino which is optionally substituted by C₁₋₄ alkyl optionally substituted by C₁₋₄ alkoxy; or a saturated or unsaturated three- to seven-membered carbocyclic or heterocyclic group; and~~

~~R¹¹ represents C₁₋₆ alkyl, C₂₋₆ alkenyl, or C₂₋₆ alkynyl (which C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl each are optionally substituted by a halogen atom or C₁₋₆ alkoxy), or R¹⁵-(CH₂)_n- wherein n is an integer of 0 to 4 and R¹⁵ represents a saturated or unsaturated three- to seven-membered carbocyclic or heterocyclic group which is optionally substituted by a halogen atom, C₁₋₆ alkyl, or C₁₋₆ alkoxy and is optionally condensed with other saturated or unsaturated three- to seven-membered carbocyclic ring or heterocyclic ring to form a bicyclic ring.~~


2. The compound according to claim 1, wherein R¹, R⁹, and R¹⁰ represent a hydrogen atom.

3. The compound according to claim 1, wherein R¹ represents a hydrogen atom and one of or both R⁹ and R¹⁰ represent a group other than a hydrogen atom.

4. The compound according to claim 1, wherein X represents N or CH and Z represents CH.

*Auth
B2*

~~5. A compound represented by formula (Ia) or a pharmaceutically acceptable salt or solvate thereof:~~

[illegible]

X represents CH or N;

R^{23} , R^{24} , R^{25} , and R^{26} , which may be the same or different, represent a hydrogen atom, a halogen atom, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} alkylthio, nitro, or amino, provided that R^{23} , R^{24} , R^{25} , and R^{26} do not simultaneously represent a hydrogen atom;

R²⁷ and R²⁸, which may be the same or different, represent a hydrogen atom, C₁₋₆ alkyl, or C₁₋₄ alkylcarbonyl, the alkyl portion of which C₁₋₆ alkyl or C₁₋₄ alkylcarbonyl is optionally substituted by a halogen atom; C₁₋₄ alkoxy; amino which is optionally substituted by C₁₋₄ alkyl optionally substituted by C₁₋₄ alkoxy; or a saturated or unsaturated three- to seven-membered

B²
Cont

6. The compound according to claim 5, wherein R²¹ and R²² represent unsubstituted C₁₋₄ alkoxy.

8. The compound according to claim 5, wherein at least one of R^{23} , R^{24} , R^{25} , and R^{26} represents a halogen atom.

10. The compound according to claim 5, wherein at least one of R^{23} , R^{24} , R^{25} , and R^{26} represents C_{1-4} alkyl.

12. The compound according to claim 5, wherein at least one of R^{23} , R^{24} , R^{25} , and R^{26} represents nitro, amino,

13. The compound according to claim 5, wherein R²³, R²⁵, and R²⁶ represent a hydrogen atom and R²⁴ represents a halogen atom, C₁₋₄ alkyl, C₁₋₄ alkoxy, nitro, or amino.

15. The compound according to claim 5, wherein any one of or both R²⁷ and R²⁸ represent a group other than a hydrogen atom.

R^{27} and R^{28} represent a hydrogen atom; and R^{29} represents C_{1-6} alkyl, C_{2-6} alkenyl, or C_{2-6} alkynyl (which C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl each are optionally substituted by a halogen atom or C_{1-4} alkoxy), or $-(CH_2)_q-R^{32}$ wherein q is an integer of 0 or 1 and R^{32} represents phenyl, pyridyl, or naphthyl which phenyl, pyridyl, and naphthyl are optionally substituted by a halogen atom, C_{1-4} alkyl, or C_{1-4} alkoxy.

any one of or both R^{27} and R^{28} represent a group other than a hydrogen atom; and

R²⁹ represents C₁₋₆ alkyl, C₂₋₆ alkenyl, or ~~C₂₋₆~~

18. The compound according to claim 5, wherein
X represents CH or N;
R²¹ and R²² represent unsubstituted C₁₋₄ alkoxy;
R²³, R²⁵, and R²⁶ represent a hydrogen atom;
R²⁴ represents a halogen atom, C₁₋₄ alkyl, C₁₋₄ alkoxy,
or nitro;
R²⁷ represents a hydrogen atom;
R²⁸ represents a group other than a hydrogen atom;
and

19. The compound according to claim 5, wherein
X represents CH or N;
any one of R²¹ and R²² represents unsubstituted C₁₋₄
alkoxy and the other represents group R³¹-(CH₂)_p-O-;
R²³, R²⁵, and R²⁶ represent a hydrogen atom;
R²⁴ represents a halogen atom, C₁₋₄ alkyl, C₁₋₄ alkoxy,
or nitro;

R^{27} and R^{28} represent a hydrogen atom; and R^{29} represents C_{1-6} alkyl, C_{2-6} alkenyl, or C_{2-6} alkynyl (which C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl each are optionally substituted by a halogen atom or C_{1-4} alkoxy), or $-(CH_2)_q-R^{32}$ wherein q is an integer of 0 or 1 and R^{32} represents phenyl, pyridyl, or naphthyl which

phenyl, pyridyl, and naphthyl are optionally substituted by a halogen atom, C₁₋₄ alkyl, or C₁₋₄ alkoxy.

20. The compound according to claim 19, wherein R²¹ represents unsubstituted C₁₋₄ alkoxy and R²² represents group R³¹-(CH₂)_p-O-.

Sub
AG
21. The compound according to claim 19 or 20, wherein R³¹ represents hydroxyl, amino on which one or two hydrogen atoms are optionally substituted by C₁₋₄ alkyl optionally substituted by hydroxyl, or group R¹⁴-(S)_m- wherein R¹⁴ represents a saturated or unsaturated five-membered heterocyclic group containing 1 to 4 nitrogen atoms and optionally substituted by C₁₋₄ alkyl, or a saturated or unsaturated six-membered heterocyclic group containing one or two hetero-atoms selected from nitrogen and oxygen atoms and optionally substituted by C₁₋₄ alkyl and m is 0 (zero); and p is an integer of 1 to 4.

22. The compound according to any one of claims 19 to 21, wherein p is 1.

23. The compound according to any one of claims 19 to 21, wherein R³¹ represents group R¹⁴-(S)_m- wherein R¹⁴ represents an unsaturated six-membered heterocyclic group containing one or two nitrogen atoms and optionally substituted by C₁₋₄ alkyl and m is 0 (zero).

24. The compound according to any one of claims 19 to 21, wherein R³¹ represents group R¹⁴-(S)_m- wherein R¹⁴ represents an unsaturated six-membered heterocyclic group containing one or two nitrogen atoms and optionally substituted by C₁₋₄ alkyl and m is 0 (zero) and p is 1.

25. The compound according to claim 23 or 24,

wherein R^{14} represents optionally substituted pyridyl.

26. The compound according to claim 5, wherein

X represents CH or N;

any one of R^{21} and R^{22} represents unsubstituted C_{1-4} alkoxy and the other represents group $R^{31}-(CH_2)_p-O-$;

R^{23} , R^{25} , and R^{26} represent a hydrogen atom;

R^{24} represents a halogen atom, C_{1-4} alkyl, C_{1-4} alkoxy, or nitro;

any one of or both R^{27} and R^{28} represent a group other than a hydrogen atom; and

R^{29} represents C_{1-6} alkyl, C_{2-6} alkenyl, or C_{2-6} alkynyl (which C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl each are optionally substituted by a halogen atom or C_{1-4} alkoxy), or $-(CH_2)_q-R^{32}$ wherein q is an integer of 0 or 1 and R^{32} represents phenyl, pyridyl, or naphthyl which phenyl, pyridyl, and naphthyl are optionally substituted by a halogen atom, C_{1-4} alkyl, or C_{1-4} alkoxy.

27. The compound according to claim 26, wherein R^{21} represents unsubstituted C_{1-4} alkoxy and R^{22} represents group $R^{31}-(CH_2)_p-O-$.

28. The compound according to claim 26 or 27, wherein R^{31} represents hydroxyl, amino on which one or two hydrogen atoms are optionally substituted by C_{1-4} alkyl optionally substituted by hydroxyl, or group $R^{14}-(S)m-$ wherein R^{14} represents a saturated or unsaturated five-membered heterocyclic group containing 1 to 4 nitrogen atoms and optionally substituted by C_{1-4} alkyl, or a saturated or unsaturated six-membered heterocyclic group containing one or two hetero-atoms selected from nitrogen and oxygen atoms and optionally substituted by C_{1-4} alkyl and m is 0 (zero); and p is an integer of 1 to 4.

29. The compound according to any one of claims 26

0900050-072304

Sub
A7

to 28, wherein p is 1.

30. The compound according to any one of claims 26 to 28, wherein R^{31} represents group $R^{14}-(S)m-$ wherein R^{14} represents an unsaturated six-membered heterocyclic group containing one or two nitrogen atoms and optionally substituted by C_{1-4} alkyl and m is 0 (zero).

31. The compound according to any one of claims 26 to 28, wherein R^{31} represents group $R^{14}-(S)m-$ wherein R^{14} represents an unsaturated six-membered heterocyclic group containing one or two nitrogen atoms and optionally substituted by C_{1-4} alkyl and m is 0 (zero) and p is 1.

32. The compound according to claim 30 or 31, wherein R^{14} represents optionally substituted pyridyl.

33. The compound according to claim 5, wherein X represents CH or N;

any one of R^{21} and R^{22} represents unsubstituted C_{1-4} alkoxy and the other represents group $R^{31}-(CH_2)p-O-$;

R^{23} , R^{25} , and R^{26} represent a hydrogen atom;

R^{24} represents a halogen atom, C_{1-4} alkyl, C_{1-4} alkoxy, or nitro;

R^{27} represents a hydrogen atom;

R^{28} represents a group other than a hydrogen atom;

and

R^{29} represents C_{1-6} alkyl, C_{2-6} alkenyl, or C_{2-6} alkynyl (which C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl each are optionally substituted by a halogen atom or C_{1-4} alkoxy), or $-(CH_2)q-R^{32}$ wherein q is an integer of 0 or 1 and R^{32} represents phenyl, pyridyl, or naphthyl which phenyl, pyridyl, and naphthyl are optionally substituted by a halogen atom, C_{1-4} alkyl, or C_{1-4} alkoxy.

34. The compound according to claim 33, wherein R^{21}

0000050 07304

sub
A8

36. The compound according to any one of claims 33 to 35, wherein p is 1.

37. The compound according to any one of claims 33 to 35, wherein R^{31} represents group $R^{14}-(S)_m-$ wherein R^{14} represents an unsaturated six-membered heterocyclic group containing one or two nitrogen atoms and optionally substituted by C_{1-4} alkyl and m is 0 (zero).

38. The compound according to any one of claims 33 to 35, wherein R^{31} represents group $R^{14}-(S)_m-$ wherein R^{14} represents an unsaturated six-membered heterocyclic group containing one or two nitrogen atoms and optionally substituted by C_{1-4} alkyl and m is 0 (zero) and p is 1.

39. The compound according to claim 37 or 38, wherein R¹⁴ represents optionally substituted pyridyl.

40. The compound according to claim 5, wherein X represents CH or N;

R²⁹ represents C₁₋₆ alkyl, C₂₋₆ alkenyl, or C₂₋₆ alkynyl (which C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl each are optionally substituted by a halogen atom or C₁₋₄ alkoxy), or -(CH₂)_q-R³² wherein q is an integer of 0 or 1 and R³² represents phenyl, pyridyl, or naphthyl which phenyl, pyridyl, and naphthyl are optionally substituted by a halogen atom, C₁₋₄ alkyl, or C₁₋₄ alkoxy.

41. The compound according to claim 40, wherein R²¹ represents unsubstituted C₁₋₄ alkoxy and R²² represents group R³¹-(CH₂)_p-O-.

42. The compound according to claim 40 or 41, wherein R³¹ represents hydroxyl, amino on which one or two hydrogen atoms are optionally substituted by C₁₋₄ alkyl optionally substituted by hydroxyl, or group R¹⁴-(S)_m- wherein R¹⁴ represents a saturated or unsaturated five-membered heterocyclic group containing 1 to 4 nitrogen atoms and optionally substituted by C₁₋₄ alkyl, or a saturated or unsaturated six-membered heterocyclic group containing one or two hetero-atoms selected from nitrogen and oxygen atoms and optionally substituted by C₁₋₄ alkyl and m is 0 (zero); and p is an integer of 1 to 4.

43. The compound according to any one of claims 40 to 42, wherein p is 1.

44. The compound according to any one of claims 40 to 42, wherein R³¹ represents group R¹⁴-(S)_m- wherein R¹⁴ represents an unsaturated six-membered heterocyclic

45. The compound according to any one of claims 40 to 42, wherein R^{31} represents group $R^{14}-(S)_m-$ wherein R^{14} represents an unsaturated six-membered heterocyclic group containing one or two nitrogen atoms and optionally substituted by C_{1-4} alkyl and m is 0 (zero) and p is 1.

47. The compound according to claim 1, which is a compound selected from the group consisting of the following compounds, or a pharmaceutically acceptable salt or solvate thereof:

(51) N-(2-chloro-4-{[6-methoxy-7-(2-morpholino-ethoxy)-4-quinolyl]oxy}phenyl)-N'-(2,4-difluorophenyl) urea;

(76) N-{2-chloro-4-[(6,7-dimethoxy-4-guinazolinyl)-oxy]phenyl}-N'-ethylurea;

(119) N-(2-chloro-4-{6-methoxy-7-(3-morpholinopropoxy)-4-quinazolinyl}oxy)phenyl)-N'-propylurea;

(135) N-(2-chloro-4-{[6-methoxy-7-(3-piperidino-
propoxy)-4-quinazolinyl]oxy}phenyl)-N'-propylurea;

(142) N-(2-chloro-4-{[6-methoxy-7-(3-pyridyl-methoxy)-4-quinolyl]oxy}phenyl)-N'-propylurea;

(143) N-(2-chloro-4-{[6-methoxy-7-(4-pyridyl-methoxy)-4-quinolyl]oxy}phenyl)-N'-propylurea;

(144) N-(2-chloro-4-{[6-methoxy-7-(2-morpholino-

(145) N-[2-chloro-4-{(6-methoxy-7-[2-(1H-1,2,3-triazol-1-yl)ethoxy]-4-quinolyl)oxy}phenyl]-N'-propylurea;

(148) N-[2-chloro-4-(6-methoxy-7-{[2-(4-methylpiperazino)ethoxy]-4-quinolyl}oxy)phenyl]-N'-propylurea;

(151) N-(2-chloro-4-{[6-methoxy-7-(3-morpholinopropoxy)-4-quinolyl]oxy}phenyl)-N'-propylurea;

(152) N-[2-chloro-4-(6-methoxy-7-{[3-(4-methylpiperazino)propoxy]-4-quinolyl}oxy)phenyl]-N'-propylurea;

(153) N-[2-chloro-4-(6-methoxy-7-{[3-(1*H*-1,2,3-triazol-1-yl)propoxy]-4-quinolyl}oxy)phenyl]-N'-propylurea;

(157) N-{2-chloro-4-[(7-{3-[(2-hydroxyethyl)-(methyl)amino]propoxy}-6-methoxy-4-quinolyl)oxy]-phenyl}-N'-propylurea;

(159) N-{2-chloro-4-[(6-methoxy-7-[[5-(1H-1,2,3-triazol-1-yl)pentyl]oxy}-4-quinolyl)oxy]phenyl}-N'-propylurea;

(160) N-[2-chloro-4-(7-{[4-(1H-1-imidazolyl)-
butoxy]-6-methoxy-4-quinolyl}oxy)phenyl]-N'-propylurea;

(162) N-(2-chloro-4-{[6-methoxy-7-(2-morpholino-ethoxy)-4-quinazolinyl]oxy}phenyl)-N'-(2,4-difluorophenyl)urea;

(163) N-(2-chloro-4-{[6-methoxy-7-(3-morpholino-propoxy)-4-quinazolinyl]oxy}phenyl)-N'-(2,4-difluorophenyl)urea;

(164) N-[2-chloro-4-(6-methoxy-7-{[3-(4-methylpiperazino)propoxy]-4-quinazolinyl}oxy)phenyl]-N'-(2,4-difluorophenyl)urea;

(165) N-{2-chloro-4-[(7-{3-[(2-hydroxyethyl)-(methyl)amino]propoxy}-6-methoxy-4-quinazolinyl)oxy]-

Sub
A10

52. A method for inhibiting the angiogenesis of target blood vessels, comprising the step of making the compound according to any one of claims 1 to 47 or a pharmaceutically acceptable salt or solvate thereof in contact with vascular endothelial cells of the target blood vessels.